Home » Keymed Biosciences Co. Ltd.

Articles Tagged with ''Keymed Biosciences Co. Ltd.''

Keymed, Platina sign $626M deal for bispecific antibody CM-336

Nov. 18, 2024

Keymed Biosciences Co. Ltd. is out-licensing global rights, excluding China, for its bispecific antibody, CM-336, to Platina Medicines Ltd. in a deal worth up to $626 million plus sales royalties.

Immuno-oncology

CM-313 exhibits strong antiproliferative activity against multiple CD38+ tumors

June 3, 2024

CD38 is a cell surface receptor, up-regulated in several types of tumors, and involved in cell activation, proliferation and differentiation.

Rona and Keymed partner to develop siRNA therapies for severe kidney diseases

May 23, 2023

By Tamra Sami

Rona Therapeutics Co. Ltd. and Keymed Biosciences Co. Ltd. formed a collaboration to jointly discover and develop first-in-class siRNA therapeutics for glomerulonephritis, also known as severe kidney diseases.

Rona and Keymed partner to develop siRNA therapies for severe kidney diseases

May 19, 2023

By Tamra Sami

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...